Breast Cancer Research and Treatment

, Volume 75, Issue 3, pp 249–258 | Cite as

The Effect of the Bisphosphonate Ibandronate on Breast Cancer Metastasis to Visceral Organs

  • Toshimi Michigami
  • Toru Hiraga
  • Paul J. Williams
  • Maria Niewolna
  • Riko Nishimura
  • Gregory R. Mundy
  • Toshiyuki Yoneda
Article

Abstract

Bisphosphonate (BPs), specific inhibitors of osteoclastic bone resorption, are widely used therapeutic agents for bone metastases in breast cancer patients. Nevertheless, the effects of BPs on visceral metastases are controversial. Here we specifically studied the effects of the BP ibandronate on visceral metastases of breast cancer using two animal models. In the first set of experiments, we examined the effects of ibandronate on lung metastasis using 4T1 mouse mammary tumor that developed pulmonary and bone metastases following orthotopic inoculation in syngeneic female Balb/c mice. In the second set of experiments, we examined the effects of ibandronate on adrenal metastasis using a clone of the MDA-MB-231 (MDA-231) human breast cancer (MDA-231AD cells) that developed adrenal and bone metastases following intracardiac inoculation in female nude mice. These breast cancer cells were stably transfected with a firefly luciferase cDNA to facilitate quantification of the metastatic tumor burden in visceral organs. Ibandronate (4 µg/day, sc, daily) was given either after metastases were established (therapeutic administration) or at the time of tumor cell inoculation (preventative administration). In both models with each protocol, ibandronate reproducibly reduced bone metastases, establishing that BPs are effective pharmacological agents for the treatment of bone metastases in breast cancer. In the 4T1 model, neither the preventative nor therapeutic administration of ibandronate caused any effects on lung metastases. In the MDA-231 model, the preventative administration of ibandronate significantly increased adrenal metastases. However, no increase in the adrenal metastases was observed when an anti-cancer agent doxorubicin was co-administered. Therapeutic administration of ibandronate showed no effects on the adrenal metastases. Our results suggest that BPs cause no adverse effects on visceral metastases when administered in the manners that breast cancer patients usually receive.

bisphosphonate bone metastasis breast cancer chemotherapy visceral metastasis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fleish H: Bisphosphonates: mechanism of action. Endocrine Rev 19: 80–100, 1998Google Scholar
  2. 2.
    Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G, Hermans Neijt JP, Papapoulos SE, Sleeboom HP, Vermey P, Zwinderman AH: Palliative pamidronate treatment in patients with bone metas-tases from breast cancer. J Clin Oncol 11: 491–498, 1993Google Scholar
  3. 3.
    Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in-patients with breast cancer and lytic bone metastases. N Engl J Med 335: 1785–1791, 1996Google Scholar
  4. 4.
    Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, Rubens RD: Current use of bisphosphonates in oncology. J Clin Oncol 16: 3890–3899, 1998Google Scholar
  5. 5.
    Mundy GR, Yoneda T: Bisphosphonates as anticancer drugs. N Engl J Med 339: 398–400, 1998Google Scholar
  6. 6.
    Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ: Pamidro-nate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17: 846–854, 1999Google Scholar
  7. 7.
    Diel IJ, Solomayer E-F, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treat-ment. N Engl J Med 339: 357–363, 1998Google Scholar
  8. 8.
    Diel IJ, Solomayer E-F, Gollan C, Shutz F, Bastert G: Bisphosphonates in the reduction of metastases in breast cancer – results of the extended follow-up of the first study population. Proceedings ASCO Abst # 314, 2000Google Scholar
  9. 9.
    McCloskey EV, Powles T, Paterson AHG, Ashley S, Kanis JA: Clodronate reduces incidence of skeletal metastases in women with primary breast cancer. Bone 23: S189, 1998Google Scholar
  10. 10.
    Saarto T, Blomqvist C, Virkkunen P, Elomaa II: adjuvant clo-dronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19: 10–17, 2001Google Scholar
  11. 11.
    Kostenuik PJ, Orr FW, Suyama K, Orr FW: Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res 53: 5452–5457, 1993Google Scholar
  12. 12.
    Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55: 3551–3557, 1995Google Scholar
  13. 13.
    Stearns ME, Wang M: Effects of alendronate and taxol on PC-3ML cell bone metastases in SCID mice. Invasion Metast 16: 116–131, 1996Google Scholar
  14. 14.
    Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T: Actions of bisphosphonate on bone metastasis in animal models of breast cancer. Cancer 88: 2979–2988, 2000Google Scholar
  15. 15.
    Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99: 2509–2517, 1997Google Scholar
  16. 16.
    Aslakson CJ, Fred R Miller: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399–1405, 1992Google Scholar
  17. 17.
    Cailleau R, Young R, Olive M, Reeves WJ Jr: Breast tu-mor cell line from pleural effusions. J Natl Cancer Inst 53: 661–674, 1974Google Scholar
  18. 18.
    Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R: A bone-seeking subclone exhibits different properties from the parental MDA-MB-231 human breast cancer cells and a brain-seeking subclone in vivo and in vitro. J Bone Miner Res 16: 1486–1495, 2001Google Scholar
  19. 19.
    Lumb G, Mackenzie DH: The incidence of metastases in ad-renal glands and ovaries removed for carcinoma of the breast. Cancer 12: 521–526, 1959Google Scholar
  20. 20.
    Muhlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6: 1003–1011, 1991Google Scholar
  21. 21.
    Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphos-phonate ibandronate promotes apoptosis in MDA-231 hu-man breast cancer cells in bone metastases. Cancer Res 61: 4418–4424, 2001Google Scholar
  22. 22.
    Kroger N, Achterrath W, Hegewisch-Becker S, Mross K, Zander AR: Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev 25: 279–291, 1999Google Scholar
  23. 23.
    Hauschka PV, Mavrokos AE, Lafrati MD, Doleman SE, Klagsbrun M: Growth factors in bone matrix. Isolation of mul-tiple types by affinity chromatography on heparin-sepharose. J Biol Chem 261: 12665–12674, 1986Google Scholar
  24. 24.
    Yoneda T, Williams PJ, Myoi A, Michigami T, Mbalaviele G: Cellular and molecular mechanisms of development of skeletal metastases. In: Body J-J (ed.) Tumor Bone Dis-eases and Osteoporosis in Cancer Patients. Marcel Dekker, New York, 2000, pp 41–69Google Scholar
  25. 25.
    Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C: Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98: 698–705, 1996Google Scholar
  26. 26.
    Boisser S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineral-ized bone extracellular matrices. Cancer Res 57: 3890–3894, 1997Google Scholar
  27. 27.
    Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG: American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18: 1378–1391, 2000Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Toshimi Michigami
    • 1
  • Toru Hiraga
    • 2
  • Paul J. Williams
    • 1
  • Maria Niewolna
    • 1
  • Riko Nishimura
    • 2
  • Gregory R. Mundy
    • 1
  • Toshiyuki Yoneda
    • 1
    • 2
  1. 1.Division of Endocrinology and Metabolism, Department of MedicineUniversity of Texas Health Science Center at San AntonioSan AntonioUSA
  2. 2.Department of BiochemistryOsaka University Graduate School of DentistrySuita, OsakaJapan

Personalised recommendations